Amyris

Morgan Stanley has published a report on Amyric Inc (NASDAQ: AMRS) in light of collaboration with Total. In the report, Morgan Stanley wrote, "We continue to reiterate our OW rating post Q2 results, which were a non-event, as quarterly financial results at this stage are not particularly...

According to J.P. Morgan, Amyris (NYSE: AMRS) reported a net loss of $33m on revenues of $37m in 1Q11. J.P. Morgan said that although revenues and net loss both exceeded consensus expectations, quarterly financial results at this stage are not particularly meaningful. “We believe investors...

JP Morgan has lowered the price target on Amyris (NASDAQ: AMRS) from $30 to $26 and maintains its Neutral rating.

Raymond James has upgraded Amyris (NASDAQ: AMRS) from Market Perform to Outperform with a $31 price target.

Morgan Stanley has downgraded Amyris, Inc. (NASDAQ: AMRS) to Equal-weight from Overweight. “Following recent share price strength, we see a balanced risk/reward as reflected in our 1:1 bull to bear ratio,” Morgan Stanley writes. “Recent partnership agreements and news flow from Total derisk the...

In a report released this morning, Morgan Stanley said that it is initiating coverage of Amyris, Inc. (NASDAQ: AMRS) with an Overweight rating, and notes that its $22 price target offers 27% upside potential. “Amyris is a biotechnology company with an advantaged position in next-generation biofuels...

J.P. Morgan is initiating coverage of Amyris, Inc. (NASDAQ: AMRS) with a Neutral rating. “Amyris is an early-stage, next-generation chemical company,” J.P. Morgan writes. “Its technology is rooted in its expertise to genetically modify yeast strains to produce chemical molecules from renewable...